Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Universal CAR-T (CT119X) in R/R B-ALL
NCT07043218Phase 1Not yet recruiting
- Sponsor
- Tongji Hospital
- Start
- Jul 2025
- Primary completion
- Jun 2026
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial in B cell acute lymphoblastic leukemia (B-ALL), sponsored by Tongji Hospital. Primary endpoints: Maximum Tolerated Dose and/or Dose Range at 28 days and Adverse Events at 12 months. Planned start Jul 2025; status: not yet recruiting.
02
Conditions
B cell acute lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on NCT07043218.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07043218.